1. Home
  2. PDCC vs ADCT Comparison

PDCC vs ADCT Comparison

Compare PDCC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDCC
  • ADCT
  • Stock Information
  • Founded
  • PDCC N/A
  • ADCT 2011
  • Country
  • PDCC
  • ADCT Switzerland
  • Employees
  • PDCC N/A
  • ADCT N/A
  • Industry
  • PDCC
  • ADCT Biotechnology: Pharmaceutical Preparations
  • Sector
  • PDCC
  • ADCT Health Care
  • Exchange
  • PDCC NYSE
  • ADCT Nasdaq
  • Market Cap
  • PDCC 135.4M
  • ADCT 143.1M
  • IPO Year
  • PDCC N/A
  • ADCT 2020
  • Fundamental
  • Price
  • PDCC $20.08
  • ADCT $1.63
  • Analyst Decision
  • PDCC
  • ADCT Strong Buy
  • Analyst Count
  • PDCC 0
  • ADCT 5
  • Target Price
  • PDCC N/A
  • ADCT $8.00
  • AVG Volume (30 Days)
  • PDCC N/A
  • ADCT 493.2K
  • Earning Date
  • PDCC N/A
  • ADCT 03-12-2025
  • Dividend Yield
  • PDCC N/A
  • ADCT N/A
  • EPS Growth
  • PDCC N/A
  • ADCT N/A
  • EPS
  • PDCC N/A
  • ADCT N/A
  • Revenue
  • PDCC N/A
  • ADCT $70,717,000.00
  • Revenue This Year
  • PDCC N/A
  • ADCT $6.81
  • Revenue Next Year
  • PDCC N/A
  • ADCT $11.23
  • P/E Ratio
  • PDCC N/A
  • ADCT N/A
  • Revenue Growth
  • PDCC N/A
  • ADCT N/A
  • 52 Week Low
  • PDCC N/A
  • ADCT $1.39
  • 52 Week High
  • PDCC N/A
  • ADCT $5.38
  • Technical
  • Relative Strength Index (RSI)
  • PDCC N/A
  • ADCT 46.49
  • Support Level
  • PDCC N/A
  • ADCT $1.55
  • Resistance Level
  • PDCC N/A
  • ADCT $1.73
  • Average True Range (ATR)
  • PDCC 0.00
  • ADCT 0.12
  • MACD
  • PDCC 0.00
  • ADCT 0.03
  • Stochastic Oscillator
  • PDCC 0.00
  • ADCT 63.16

About PDCC PEARL DIVER CREDIT COMPANY INC

PEARL DIVER CREDIT COMPANY INC is a non-diversified closed ended management investment company.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Share on Social Networks: